OPTN - OptiNose Inc Debt to Book Capitalization Ratio

Graphic logo of OptiNose Inc (OPTN)

Demand for prescription nasal products at OptiNose, Inc. (OPTN) remains stable, as insurance offsets the impact of macroeconomic shocks. High-precision robotic assembly lines ensure the flawless construction of drug delivery system components. The current balance sheet leverage ratio reflects the dynamics of the credit load, with the level sitting around 0.00. While clinical inertia supports spray sales, aggressive marketing is reducing free cash flow.

OPTN (OptiNose Corp) Debt to Book Value history from 07/04/2022 to 05/31/2025
Core merchandise of Optinose

Analyzing the capital structure allows for the decoupling of market volatility from the fundamental stability of the business. This indicator measures the proportion of borrowed funds within the total book value of assets, determining the degree of financial leverage. The current debt-to-equity ratio visualizes the dynamics of the debt load in real-time. For OptiNose, Inc. (OPTN), this is critical when scaling sales of its nasal spray. Controlling this ratio confirms management's ability to maintain a safe operating margin.

Competitors of OptiNose, Inc.

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio TNXP (tonixpharma.com)|SXTC: Debt to Book Capitalization Ratio|Eupraxia Pharmaceuticals, Inc. - Debts to Book Value|Debt to Book Capitalization Ratio BioHarvest|Invizyne (EXOZ) - Debts to Book Capitalization Ratio|ORMP - Debt to Book Value|Entera Bio (ENTX) - Debt to Book Capital|HYFT: Debts to Book Capitalization|Debts to Net Assets ABVC|Debt to Book Capitalization Ratio Cumberland Pharma CPIX|Debt to Book Value Ratio QNTM (Quantum BioPharma Corp)|FGEN: Debt to Book Capitalization Ratio|telomirpharma.com - Debts to Book Value|Debt to Book Capitalization Ratio RANI (Rani Therapeutics Inc)|SNYR - Debts to Net Assets|Debts to Book Capitalization RLYB|Debts to Book Value Lexaria Bioscience Corp.|PULM - Debt to Book Value|Debt to Net Assets Ratio Pheton|APM (Aptorum Group Limited) - Debts to Book Capitalization|Debts to Net Assets LYRA (Lyra Therapeutics Inc.)|IBO - Debt to Book Capitalization Ratio|Debt to Book Value Ratio TNF Pharmaceuticals Inc. TNFA|YCBD: Debts to Book Capitalization|painreform.com (PRFX) - Debt to Book Value|altamiratherapeutics.com - Debt to Book Value|LIPO (Lipella Pharmaceuticals Inc) - Debts to Net Assets|Debt to Book Capitalization Ratio PIRS (Pieris)|Debts to Book Value PROC|PTPI - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio qlsyy.net QLI|Debt to Book Value ACELYRIN (SLRN)|TFF Pharmaceuticals Inc. - Debt to Book Capital